Business
-
Over the past 8 months, says API developer and manufacturer Hovione, its facilities have undergone a total of 6 inspections by the US FDA, the Japanese PMDA, and the Portuguese authorities. Pre-approval inspections for 2… Read more . . .
-
Rigel Pharmaceuticals says it will assume development responsibilities for R343, an inhaled syk inhibitor for the treatment of allergic asthma after Pfizer returned all rights to the program. Pfizer had licensed R343, along with other… Read more . . .
-
According to reports, GlaxoSmithKline has invested an additional $6.7 million in Theravance, its partner in developing a number of inhaled asthma and COPD drugs. The purchase of common stock gives GSK approximately 19% of Theravance’s… Read more . . .
-
Steroid manufacturers Sterling S.r.l., located in Perugia, Italy, is now producing APIs for respiratory delivery using particle engineering technology supplied by Prosonix. A two-year collaboration between the two companies has resulted in a retrofit of… Read more . . .
-
MicroDose Therapeutx has announced that it has achieved a milestone that “signals the successful incorporation of MicroDose’s DPI technology into a Novartis platform pulmonary device” and triggers a milestone payment from Novartis. The two companies… Read more . . .
-
A number of companies that provide products and services to developers and manufacturers of inhaled and nasal drug products have been named as recipients of the 2011 Queen’s Awards for Enterprise. The Queen presents the… Read more . . .
-
According to Luitpold Pharmaceuticals, its suspension of both manufacturing at its Shirley, NY facility and distribution of products manufactured at that location, will not affect Sprix ketorolac tromethamine nasal spray. The company says that it… Read more . . .
-
The University of Michigan will license an antigen to NanoBio Corporation for development of a nasal vaccine using NanoBio’s NanoStat technology for the prevention of urinary tract infections (UTIs). The antigen works by eliminating E.… Read more . . .
-
Gilead Sciences and MicroDose Therapeutx have reached an agreement for the development and commercialization of MDT-637, a small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV). The dry powder formulation is… Read more . . .
-
European specialty pharma company Axcan will acquire Mpex Pharmaceuticals and its lead candidate, Aeroquin levofloxacin inhalation solution for the treatment of Pseudomonas aeruginosa infections in CF patients, which is currently in Phase 3 trials. Axcan… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland